European Pharmaceutical Review

NOVEMBER 21, 2024

Prior to his work in the biopharma industry, Dr Boshoff was founding Director of the University College London (UCL) Cancer Institute. He earned his medical degree from University of Pretoria in South Africa, a doctorate PhD from the Institute of Cancer Research in London. Academy of Medical Sciences. “I

Medicine 59

Medicine Medical science Biopharma Medical 59

pharmaphorum

DECEMBER 23, 2022

With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance. Leading companies will empower their teams to act quickly, compliantly, and with a unified view of the HCP.”.

Marketing 97

Marketing Sales Medical Patients 97

Clarify Health

MAY 19, 2020

There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. sales, medical science liaisons, etc.).

Biopharma 52

Biopharma Physicians Marketing Prescription 52

Medgadget

FEBRUARY 17, 2023

Thanks to kind support from Biomed Israel , the leading international Life Science and HealthTech conference in Israel (see more below), we met with Ronan Castro, the CEO of Human Xtensions at the company’s offices in Netanya, Israel. More info can be found at the Biomed Israel website.

Physicians 80

Physicians Engineering Leads Side effects 80

Medgadget

MARCH 2, 2023

This leads to substantial damage to healthy tissues and too often results in poor outcomes. This will hopefully lead to an FDA approval for its first indication, after which Alpha TAU plans on expanding to other types of cancer and geographic regions such as Europe and Japan. which are currently recruiting patients.

Manufacturing 82

Manufacturing Leads Patients Medicine 82

Clarivate

JUNE 21, 2024

While the exponential growth of publications in the field of medical science presents a challenge for human reviewers, AL/ML algorithms can excel here as they do not suffer from fatigue while dealing with such large data sets. An additional concern is the opaque nature of the algorithms.

Training 81

Training Government Medical science Ethics 81